Leukaemia Section
Mini Review

**t(4;14)(p16;q32)**

Frank Viguié

Laboratoire de Cytogénétique - Service d'Hématologie Biologique, Hôpital Hôtel-Dieu, 75181 Paris Cedex 04, France (FV)

Published in Atlas Database: May 2005

Online updated version: [http://AtlasGeneticsOncology.org/Anomalies/t04142059.html](http://AtlasGeneticsOncology.org/Anomalies/t04142059.html)

DOI: 10.4267/2042/38220


This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2005 Atlas of Genetics and Cytogenetics in Oncology and Haematology

### Clinics and pathology

**Disease**
Found in plasma cell leukaemia, multiple myeloma, plasmacytoma and monoclonal gammopathy of unknown significance (MGUS).

**Phenotype/cell stem origin**
Malignant plasma cells have the phenotype of mature terminally differenciated B-cells; there origin may be a pluripotent stem cell.

**Epidemiology**
Poorly described before FISH, quite karyotypically undetectable: found initially in cell lines, it represents the second more frequent IgH associated rearrangement, after t(11;14); detected by interphase FISH or RT-PCR in 25% MM cell lines, 15-20% primary MM and 0-10% MGUS lines; might be frequent but karyotypically undetected.

**Clinics**
Found in MM cases with unfavorable prognosis, even in patients treated with high dose chemotherapy.

### Additional anomalies
Hypodiploid karyotype and -13 / 13q- in major part of cases.

### Genes involved and proteins

**FGFR3**

**Location**
4p16.3

![c-FGFR3 (4p16.3) in normal cells: PAC 884J17 - Courtesy Mariano Rocchi, Resources for Molecular Cytogenetics.](image)

**Protein**
Member of the tyrosine-kinase FGF receptor family, contains an extracellular domain with Ig-like loops, a transmembrane domain, and intracellular tyrosine kinase domains; localisation: plasma membrane; tyrosine kinase receptor; role in signal transduction, activates multiple signaling pathways regulating cell proliferation and differentiation; constitutional point mutations resulting in ligand-independent activation, are responsible of familial dominant achondroplasia / thanatophoric dwarfism.

**IgH**

**Location**
14q32
**MMSET (multiple myeloma SET domain), also known as WHSC1 (Wolf-Hirschhorn syndrome candidate 1)**

**Location**
4p16.3

**DNA/RNA**
90 kb, 25 exons, 5' - 3' centromeric orientation - complex alternative splicing.

**Protein**
136 KDa, 4 domains: PWWP domain (proline-tryptophan-tryptophan-prolin motif), HMG box (high mobility group), PHD-type (plant-homeodomain) zinc finger domain and SET (suppressor of variegation enhancer of zeste and Trithorax) domain. One full length 1365 aa isoenzyme and 4 possible truncated variants. Transcription factor, ubiquitously expressed but preferentially in growing embryonic tissues. Chromatin remodelling agent, regulates histones methylation. Constitutional deletion of one copy is responsible for Wolf-Hirschhorn syndrome by haplo-insufficiency.

**Result of the chromosomal anomaly**

**Hybrid gene**

**Description**
4p16.3 breakpoint in a 110 kb region between MMSET (centromeric) within the 5' introns, and FGFR3 (telomeric). 14q32 breakpoint in the IgH switch region involving JH + constant region.

Two fusions generated, FGFR3 brought under the influence of the Ig gene enhancer Ea on der(14); MMSET under the influence of enhancer Eµ on der(4).

Both FGFR3 and MMSET genes are deregulated by the translocation and a IgH-MMSET fusion transcript, detectable by RT-PCR, is generated.

**Fusion protein**

**Description**
No IgH-FGFR3 fusion protein, but promoter exchange between both partner genes; however, somatic mutations similar to what has been found in thanatophoric dwarfism have been identified in some cases; they may also contribute to abnormal FGFR3 activation. According to the variable breakpoint inside MMSET gene, the translocation may generate either a full length MMSET protein or a NH2-terminal truncated one.

**Oncogenesis**

Overexpression and activation of FGFR3 provides an oncogenic signal enhancing cell proliferation and survival. The functional consequences of MMSET deregulation are not completely investigated. All t(4;14) positive cases express MMSET whereas 30% lack FGFR3 expression, sometimes correlated with loss of der(14), which tends to demonstrate that MMSET dysregulation should be the crucial oncogenic event.

**References**


Chesi M, Nardini E, Brents LA, Schröck E, Ried T, Kuehl WM, Bergsagel PL. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997 Jul;16(3):260-4


Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998 Nov 1;92(9):3025-34


This article should be referenced as such: